Heteroaryl derivatives

Abstract

A compound of the following formula (1), or its prodrug or pharmaceutically acceptable salt thereof, being useful as a diabetic medicine or preventive, or blood sugar regulator, or therapeutic agent for hyperlipemia, etc. wherein the ring Z is an optionally substituted heteroaryl, W 4 is a single bond, lower alkylene, etc., Ar 2 is an optionally substituted aryl, etc., W 3 is a single bond, lower alkylene, etc., Ar 1 is an optionally substituted arylene, etc., each of W 1 and W 2 is an optionally substituted lower alkylene, etc., and R 1 is carboxyl, an alkoxycarbonyl.

1 . A compound of the formula (1): 
       
         
           
           
               
               
           
         
         wherein Ring Z is an optionally substituted heteroaryl ring except for an indole ring; 
         W 4  is a single bond, —NR 10 —, —NR 10 —W 6 — (in which R 10  is a hydrogen atom, or an optionally substituted lower alkyl, and W 6  is a lower alkylene), a lower alkylene, or a lower alkenylene; 
         Ar 2  is an optionally substituted aryl or an optionally substituted heteroaryl; 
         W 3  is a single bond, a lower alkylene, a lower alkenylene, or —Y 1 —W 5 —, in which Y 1  is an oxygen atom, a sulfur atom, —S(O)— or —S(O) 2 —, and W 5  is a lower alkylene or a lower alkenylene; 
         Ar 1  is an optionally substituted arylene or an optionally substituted heteroarylene; 
         W 1  and W 2  are independently an optionally substituted lower alkylene or an optionally substituted lower alkenylene; 
         R 1  is a carboxyl group, an alkoxycarbonyl group, an optionally substituted carbamoyl group, an optionally substituted cyclic aminocarbonyl group, an optionally substituted alkylsulfonylcarbamoyl group, an optionally substituted arylsulfonylcarbamoyl group, or a tetrazolyl group; 
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         2 . The compound according to  claim 1 , wherein Ring Z is a group selected from the group consisting of an optionally substituted pyrrole ring, an optionally substituted pyrazole ring, an optionally substituted imidazole ring, an optionally substituted triazole ring, an optionally substituted indazole ring, an optionally substituted benzimidazole ring,
 a group represented by following formula (2);   
       
         
           
           
               
               
           
         
         
           wherein the number of R 11  is zero or one or more, and R 11  is a halogen atom, an optionally substituted lower alkyl group, an optionally substituted alkoxy group, hydroxy group, an optionally substituted amino group, or oxo group, 
         
         n is 1, 2 or 3, 
         or a group selected from the group consisting of the following formulae (11): 
       
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         and said group may be substituted; 
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         3 . The compound according to  claim 2 , wherein Ring Z is a group selected from the group consisting of following formulae (A); 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         wherein the number of R 2  may be zero, or one or more, and R 2  is independently a halogen atom, an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, or an optionally substituted thiol; 
         And wherein the number of R 3  may be zero, one or more, and R 3  is independently, a halogen atom, an optionally substituted alkyl, an optionally substituted thiol, an optionally substituted alkoxy group, an optionally substituted amino, hydroxy group, cyano group, nitro group, an optionally substituted acyl group, an optionally substituted saturated heterocyclic group, or an optionally substituted carbamoyl group, and the number of R 11  may be zero, one or more, and R 11  is independently, a halogen atom, an optionally substituted alkyl, an optionally substituted alkoxy group, hydroxy group, an optionally substituted amino, or an oxo group, and n is 1, 2 or 3 and the binding position thereof is not limited; 
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         4 . The compound according to  claim 1 , wherein W 1  or W 2  is a lower alkylene. 
     
     
         5 . The compound according to  claim 1 , wherein Ring Z is a group selected from the group represented by the following formulae; 
       
         
           
           
               
               
           
         
         wherein the number of R 2  may be zero, or one or more, and R 2  is independently a halogen atom, an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, or an optionally substituted thiol; 
         And wherein the number of R 3  may be zero, one or more, and R 3  is independently, a halogen atom, an optionally substituted alkyl, an optionally substituted thiol, an optionally substituted alkoxy group, an optionally substituted amino, hydroxy group, cyano group, nitro group, an optionally substituted acyl group, an optionally substituted saturated heterocyclic group, or an optionally substituted carbamoyl group, and the number of R 11  may be zero, one or more, and R 11  is independently, a halogen atom, an optionally substituted alkyl, an optionally substituted alkoxy group, hydroxy group, an optionally substituted amino, or an oxo group, and n is 1, 2 or 3 and the binding position thereof is not limited; 
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         6 . A pharmaceutical composition comprising the compound according to any one of  claims 1  to  4 , or a pharmaceutically acceptable salt thereof, as an active ingredient and a pharmaceutically acceptable carrier. 
     
     
         7 . A method for treating diabetes mellitus or hyperlipidemia by administering to a patient who needs for treatment of it an effective amount of the compound according to any one of  claims 1  to  4 , or a pharmaceutically acceptable salt thereof.